Andrew Hirsch is the CEO of C4 Therapeutics, Inc., a biotechnology company he joined in October 2020. He earned his M.B.A. from the Tuck School at Dartmouth and has a B.A. in Economics from the University of Pennsylvania. Before leading...
Andrew Hirsch is the CEO of C4 Therapeutics, Inc., a biotechnology company he joined in October 2020. He earned his M.B.A. from the Tuck School at Dartmouth and has a B.A. in Economics from the University of Pennsylvania. Before leading C4, he was the Chief Financial Officer at Agios Pharmaceuticals, where he helped develop corporate strategies. Hirsch has also been the CEO of BIND Therapeutics, another biotech firm. His experience spans years in various leadership roles at companies like Biogen and Avila Therapeutics. Under his watch, C4 Therapeutics has focused on innovative treatments in clinical development, specifically protein degradation therapies, which have the potential to revolutionize cancer treatment. In 2023, his total compensation was around $665,200, which includes a significant amount of restricted stock units tied to company performance. He is also known for strategic insider trading, peaking his holdings value at about $3.19 million last September. Throughout his career, Hirsch remains committed to aligning executive interests with company success.